Journal
NEUROLOGY
Volume 86, Issue 16, Pages 1553-1556Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0000000000002594
Keywords
-
Categories
Funding
- NIAID NIH HHS [U19 AI046130, P01 AI045757, P01 AI039671, U19 AI070352] Funding Source: Medline
- NIGMS NIH HHS [T32 GM007205] Funding Source: Medline
Ask authors/readers for more resources
Ipilimumab is a monoclonal antibody that prolongs survival in patients with metastatic melanoma.(1) It targets the coinhibitory receptor cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). CTLA-4 signaling induces a state of T-cell unresponsiveness, which facilitates tumor escape from immune surveillance. Blockade of CTLA-4 is believed to shift the immune status from T-cell exhaustion to a functional antitumor response. Anti-CTLA-4 therapy is associated with immune-related adverse events in 64% of patients. Autoimmunity involving the nervous system has a low incidence and manifests predominantly as peripheral inflammatory neuropathy.(2) We report new-onset inflammatory CNS demyelination in an ipilimumab-treated melanoma patient (figure), confirmed by histology and associated with enhanced responses of myelin-reactive CD4+ T cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available